Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 18/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18928137 | 0.92 | PDE1A (0.87) | PDE1APDE1BPDE4A | |
| SCHEMBL2472569 | 0.92 | PDE1A (0.87) | PDE1APDE1BPDE4A | |
| SCHEMBL15869800 | 0.92 | PDE1A (0.84) | PDE1APDE1BPDE4A | |
| SCHEMBL14243419 | 0.92 | PDE1A (1.00) | PDE1APDE1BPDE4A | |
| SCHEMBL2507601 | 0.91 | PDE4A (1.00) | PDE1APDE1BPDE4A | |
| SCHEMBL18927849 | 0.91 | PDE4A (1.00) | PDE1APDE1BPDE4A | |
| SCHEMBL14243423 | 0.89 | PDE4A (0.85) | PDE1APDE1BPDE4A | |
| SCHEMBL29790189 | 0.89 | PDE4A (0.85) | PDE1APDE1BPDE4A | |
| SCHEMBL14158310 | 0.89 | PDE4A (0.85) | PDE1APDE1BPDE4A | |
| SCHEMBL7522782 | 0.87 | PDE4A (0.80) | PDE1APDE1BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138820-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200138820-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2020-05-07 | — | — | US | disclosed |
| US-10561656-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10561656-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2717877-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2717877-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20140194396-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194396-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194396-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2012171016-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138820-A1 | ORGANIC COMPOUNDS | PDE3A, PDE3B, PDE5A | PDE1A 40/4885PDE1B 35/4885PDE4A 7/4885 |
| US-20140194396-A1 | ORGANIC COMPOUNDS | PDE3A, PDE3B, PDE5A | PDE1A 40/4885PDE1B 35/4885PDE4A 7/4885 |
| US-10561656-B2 | Organic compounds | PDE3A, PDE3B, PDE5A | PDE1A 40/4885PDE1B 35/4885PDE4A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.